TrialINB03 for the Treatment of Pulmonary Complications From COVID-19
Trial details
- Registry ID
- NCT04370236
- Phase
- Phase 2, Phase 3
INMB
Inmune Bio, Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
3Trials in this database
3Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| INB03 for the Treatment of Pulmonary Complications From COVID-19NCT04370236 | INMB | Phase 2, Phase 3 | Terminated | 2021-10-13Actual |
| A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of InflammationNCT05318976 | INMB | Phase 2 | Completed | 2025-05-12Actual |
| An Open-Label Extension of XPro1595 in Patients With Alzheimer's DiseaseNCT05522387 | INMB | Phase 2 | Terminated | 2024-06-05Actual |
A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation
Trial details
- Registry ID
- NCT05318976
- Phase
- Phase 2
An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
Trial details
- Registry ID
- NCT05522387
- Phase
- Phase 2
Latest recorded trial changes
A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation
NCT05318976 · Inmune Bio, Inc.
Actual enrollment decreased by 1 participants
− Before
208 participants (actual)
+ After
207 participants (actual)
An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
NCT05522387 · Inmune Bio, Inc.
Recruitment status changed
− Before
Active not recruiting
+ After
Terminated
INB03 for the Treatment of Pulmonary Complications From COVID-19
NCT04370236 · Inmune Bio, Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Proportion of Participants With Disease Progression From Randomization to 28 Days Post-randomization
+ After
Measure: Cochran-Mantel-Haenszel Analysis of Proportion of Patients With Disease Progression